Oscar Health Inc OSCR.N, OSCR.K is expected to show a rise in quarterly revenue when it reports results on February 4 for the period ending December 31 2024
The New York City-based company is expected to report a 72.9% increase in revenue to $2.475 billion from $1.43 billion a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Oscar Health Inc is for a loss of 59 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and 2 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Oscar Health Inc is $19.00, above its last closing price of $17.30.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.18 | -0.17 | -0.22 | Missed | -28.3 |
Jun. 30 2024 | 0.17 | 0.16 | 0.20 | Beat | 23.7 |
Mar. 31 2024 | 0.27 | 0.27 | 0.62 | Beat | 127.9 |
Dec. 31 2023 | -0.73 | -0.72 | -0.66 | Beat | 8.7 |
Sep. 30 2023 | -0.47 | -0.47 | -0.29 | Beat | 38.6 |
Jun. 30 2023 | -0.22 | -0.23 | -0.07 | Beat | 69.6 |
Mar. 31 2023 | -0.04 | -0.05 | -0.18 | Missed | -254.7 |
Dec. 31 2022 | -1.09 | -1.16 | -1.05 | Beat | 9.5 |
This summary was machine generated January 31 at 21:27 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。